Sickle cell disease and acute leukemia: one case report and an extensive review.
Acute myeloid leukemia
Prognosis
Sickle cell disease
Treatment
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
20
03
2023
accepted:
22
05
2023
medline:
14
6
2023
pubmed:
3
6
2023
entrez:
3
6
2023
Statut:
ppublish
Résumé
Population-based studies and case reports suggest that there may be an increased risk of acute leukemia associated with sickle cell disease (SCD). Following the description of a new case report, an extensive review of the literature identified 51 previously described cases. Most cases study showed myelodysplastic features confirmed, when available, by genetic markers such as chromosome 5 and/or chromosome 7 abnormalities and TP53 gene mutations. The increased risk of leukemogenesis is certainly multifactorial and related to the pathophysiologic mechanisms of the clinical manifestations of SCD. Chronic hemolysis and secondary hemochromatosis may cause increased chronic inflammation, resulting in persistent marrow stress, which could potentially compromise the genomic stability of the hematopoietic stem cells generating genomic damage and somatic mutations over the course of SCD and its treatment, resulting in a clone that led to acute myeloid leukemia.
Identifiants
pubmed: 37269388
doi: 10.1007/s00277-023-05294-3
pii: 10.1007/s00277-023-05294-3
pmc: PMC10239223
doi:
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1657-1667Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561–1573
pubmed: 28423290
doi: 10.1056/NEJMra1510865
Herrick JD (1910) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 6:517–521
doi: 10.1001/archinte.1910.00050330050003
Goldin AG, Kelty KC, Beard MF (1953) Sickle cell anemia terminating in acute myeloblastic leukemia. Ann Intern Med 39:920–928
pubmed: 13092745
doi: 10.7326/0003-4819-39-4-920
Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Brunson A, Keegan THM, Bang H et al (2017) Increased risk of leukemia among sickle cell disease patients in California. Blood 130:1597–1599
pubmed: 28830890
pmcid: 5620417
doi: 10.1182/blood-2017-05-783233
Seminog OO, Ogunlaja OI, Yeates D et al (2016) Risk of individual malignant neoplasms in patients with sickle cell disease: English National Record Linkage Study. J R Soc Med 109:303–309
pubmed: 27325377
pmcid: 4976723
doi: 10.1177/0141076816651037
Jackson RE, Short BJ (1972) Frequency and prognosis of coexisting sickle cell disease and acute leukemia in children. Clin Pediatr 183:183–185
doi: 10.1177/000992287201100313
Samal GC (1979) Sickle cell anemia with acute myeloid leukemia – (a case report). Indian Pediatr 16:453–454
pubmed: 292624
Conference C (1982) Left elbow pain and death in a young woman with sickle-cell anemia. Am J Med 73:268–282
doi: 10.1016/0002-9343(82)90189-9
Johnson FL, Look AT, Gockerman J et al (1984) Bone marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 311:780–783
pubmed: 6382010
doi: 10.1056/NEJM198409203111207
Bigner SH, Friedman HS, Kinney TR et al (1986) 9p− in a girl with acute lymphocytic leukemia and sickle cell disease. Cancer Genet Cytogenet 21:267–269
pubmed: 3456265
doi: 10.1016/0165-4608(86)90007-5
Stricker RB, Linker CA, Crowley TJ, Embury SH (1986) Hematology malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol 21:223–230
pubmed: 3455791
doi: 10.1002/ajh.2830210212
Njoku OS, Johnson SB, Kulkarni AG, Mba EC (1988) Acute lymphoblastic leukaemia in a Nigerian adult with sickle cell anaemia. Centr Afr J Med 34:158–160
Sotomayer EA, Glasser L (1999) Acute lymphoblastic leukemia in sickle cell disease. Arch Pathol Lab Med 123:744–745
De Montalembert M, Bégué P, Bernaudin F et al (1999) Preliminary report of a toxicity study of hydroxyurea in sickle cell disease: French Study Group on Sickle Cell Disease. Arch Dis Child 81:437–439
pubmed: 10519721
pmcid: 1718114
doi: 10.1136/adc.81.5.437
Rauch A, Borromeo M, Ghafoor A et al (1999) Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood 94(suppl.1):415a
Wilson S (2000) Acute leukemia in a patient with sickle cell anemia treated with hydroxyurea. Ann Intern Med 133:925–926
pubmed: 11103075
doi: 10.7326/0003-4819-133-11-200012050-00029
Al-Jam’a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG (2002) Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J 23:1411–1413
pubmed: 12506308
Schultz WH, Ware RE (2003) Malignancy in patients with sickle cell disease. Am J Hematol 74:249–253
pubmed: 14635205
doi: 10.1002/ajh.10427
Ferster A, Sariban E, Meuleman N (2003) Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 123:368–369
pubmed: 14531924
doi: 10.1046/j.1365-2141.2003.04614.x
Taylor JG, Darari DS, Maric I et al (2011) Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. Ann Intern Med 155:722–724
pubmed: 22084346
pmcid: 3508679
doi: 10.7326/0003-4819-155-10-201111150-00024
Baz W, Najfeld V, Yotsuya M et al (2012) Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol 6:149–152
pubmed: 22550403
pmcid: 3306229
doi: 10.4137/CMO.S8810
Zemenides S, Erblich T, Luqmani A, Bain BJ (2014) Peripheral blood features of acute myeloid leukemia with myelodysplasia-related changes developing in a patient with sickle cell anemia. Am J Hematol 89:1010
pubmed: 24852219
doi: 10.1002/ajh.23768
Aumont C, Driss F, Lazure T et al (2015) Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol 90:E131–E132
pubmed: 25801602
doi: 10.1002/ajh.24010
Chauhan S, Swain SK, Sahu MC (2018) Incidence of hematological malignancies in sickle cell patients from an Indian tertiary care teaching hospital. Asian J Pharm Clin Res 11:205–209
doi: 10.22159/ajpcr.2018.v11i3.22790
Janakiram M, Verma A, Wang Y et al (2018) Accerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leuk Lymphoma 59:241–244
pubmed: 28587497
doi: 10.1080/10428194.2017.1324158
Li Y, Maule J, Neff JL et al (2019) Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Modern Pathol 32:1712–1726
doi: 10.1038/s41379-019-0325-6
Eapen M, Brazauskas R, Walters MC et al (2019) Impact of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective, cohort study. Lancet Haematol 6:e585–e596
pubmed: 31495699
pmcid: 6813907
doi: 10.1016/S2352-3026(19)30154-1
Regan S, Yang X, Finnberg NK et al (2019) Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer Biol Ther 20:1389–1397
pubmed: 31423878
pmcid: 6804808
doi: 10.1080/15384047.2019.1647055
Aworanti OW, Fasola FA, Kotila TR et al (2020) Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: a case series. Afri Health Sci 20:1304–1312
doi: 10.4314/ahs.v20i3.36
Yadav DK, Paul T, Alhamar M et al (2020) Pure erythroid leukemia in a sickle cell patient treated with hydroxyurea. Case Rep Oncol 13:857–862
pubmed: 32884531
pmcid: 7443646
doi: 10.1159/000508361
Ghannam JY, Xu X, Maric I et al (2020) Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood 135:1185–1188
pubmed: 32062672
pmcid: 7118814
Chellapandian D, Nicholson CL (2020) Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia. Pediatr Transplant 24:e13641
pubmed: 31880407
doi: 10.1111/petr.13641
Hsieh MM, Bonner M, Pierciey FJ et al (2020) Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv 4:2058–2063
pubmed: 32396618
pmcid: 7218414
doi: 10.1182/bloodadvances.2019001330
Ahmed IO, Ochogwu LO, Owojuyigbe TO et al (2021) Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report. J Med Case Reports 15:504
doi: 10.1186/s13256-021-03060-5
Goyal S, Tisdale J, Schmidt M et al (2022) Acute myeloid leukemia after gene therapy for sickle cell disease. N Engl J Med 386:138–147
pubmed: 34898140
doi: 10.1056/NEJMoa2109167
Flevari P, Voskaridou E, Galacteros F et al (2022) Case report of myelodysplastic syndrome in a sickle-cell disease patient treated with hydroxyurea and literature review. Biomedicines 10:3201
pubmed: 36551957
pmcid: 9775156
doi: 10.3390/biomedicines10123201
Paydas S (2002) Sickle cell anemia and hematological neoplasias. Leuk Lymphoma 43:1431–1434
pubmed: 12389625
doi: 10.1080/1042819022386833
Dawkins FW, Kim KS, Squires RS et al (1997) Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986–1995. Am J Hematol 55:188–192
pubmed: 9257878
doi: 10.1002/(SICI)1096-8652(199707)55:4<188::AID-AJH4>3.0.CO;2-O
Green NS, Barral S (2014) Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res 75:196–204
pubmed: 24252885
doi: 10.1038/pr.2013.227
Steinberg MH, Barton F, Castro O et al (2003) Effect of hydroxyurea on mortalityand morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645–1651
pubmed: 12672732
doi: 10.1001/jama.289.13.1645
Charache S, Terrin ML, Moore RD et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317–1322
pubmed: 7715639
doi: 10.1056/NEJM199505183322001
Ferster A, Vermylen C, Cornu G et al (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88:1960–1964
pubmed: 8822914
doi: 10.1182/blood.V88.6.1960.bloodjournal8861960
Wang WC, Ware RE, Miller ST et al (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377:1663–1672
pubmed: 21571150
pmcid: 3133619
doi: 10.1016/S0140-6736(11)60355-3
Da Silva Rocha LB, Dias Elias DB, Barbosa MC et al (2012) DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype. Mutat Res 749:48–52
pubmed: 22918118
doi: 10.1016/j.mrgentox.2012.08.003
Maia Filho PA, Pereira JF, Almeida Filho TPD et al (2019) Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environ Mol Mutagen 60:302–304
pubmed: 30525240
doi: 10.1002/em.22260
Kiladjian JJ, Chevret S, Dosquet C et al (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907–3913
pubmed: 21911721
doi: 10.1200/JCO.2011.36.0792
Lanzkron S, Strouse JJ, Wilson R et al (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell diseases. Ann Intern Med 148:939–955
pubmed: 18458272
pmcid: 3256736
doi: 10.7326/0003-4819-148-12-200806170-00221
Steinberg MH, McCarthy WF, Castro O et al (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 85:403–408
pubmed: 20513116
pmcid: 2879711
Voskaridou E, Christoulas D, Bilalis A et al (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115:2354–2363
pubmed: 19903897
doi: 10.1182/blood-2009-05-221333
Castro O, Nouraie M, Oneal P (2014) Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol 167:687–691
pubmed: 25146244
doi: 10.1111/bjh.13093
Kinney TR, Helms RW, O’Branski EE et al (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 94:1550–1554
pubmed: 10477679
Ferster A, Tahriri P, Vermylen C et al (2001) Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97:3628–3632
pubmed: 11369660
doi: 10.1182/blood.V97.11.3628
Flanagan JM, Howard TA, Mortier N et al (2010) Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 698:38–42
pubmed: 20230905
pmcid: 5831106
doi: 10.1016/j.mrgentox.2010.03.001
Rodriguez A, Duez P, Dedeken L et al (2018) Hydroxyurea (hydroxycarbamine) genotoxicity in pediatric patients with sickle cell disease. Pediatr Blood Cancer 65:e27022
pubmed: 29512872
doi: 10.1002/pbc.27022
Ware RE, Dertinger SD (2021) Absence of hydroxyurea-induced mutational effects supports higher utilization for the treatment of sickle cell anaemia. Br J Haematol 194:252–266
pubmed: 33570176
doi: 10.1111/bjh.17323
Hanft V, Fruchtman S, Pickens C et al (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95:3589–3593
pubmed: 10828048
doi: 10.1182/blood.V95.11.3589
De Montelembert M, Voskaridou E, Oevermann L et al (2021) Real-life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol 96:1223–1231
doi: 10.1002/ajh.26286
Vermylen C (2003) Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev 17:163–166
pubmed: 12818226
doi: 10.1016/S0268-960X(03)00006-7
Gluckman E, Cappelli B, Bernaudin F et al (2017) Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 129:1548–1556
pubmed: 27965196
pmcid: 5356458
doi: 10.1182/blood-2016-10-745711
Locatelli F, Rocha V, Reed W et al (2003) Related umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 101:2137–2143
pubmed: 12424197
doi: 10.1182/blood-2002-07-2090
Kamani NR, Walters MC, Carter S et al (2012) Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 18:1265–1272
pubmed: 22343376
pmcid: 3618440
doi: 10.1016/j.bbmt.2012.01.019
Abraham A, Cluster A, Jacobsohn D et al (2017) Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant 23:1587–1592
pubmed: 28578010
doi: 10.1016/j.bbmt.2017.05.027
Aydin M, Dovern E, Leeflang MMG et al (2021) Haploidentical allogeneic stem cell transplantation in sickle cell disease: a systematic review and meta-analysis. Transplant Cell Ther 27:1004.e1-1004.e8
pubmed: 34537420
doi: 10.1016/j.jtct.2021.09.009
Jones RJ, DeBaun MR (2021) Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood 138:942–947
pubmed: 34115136
doi: 10.1182/blood.2021011488
Kanter J, Walters MC, Krishnamurti L et al (2022) Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med 386:617–628
pubmed: 34898139
doi: 10.1056/NEJMoa2117175
Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405–1413
pubmed: 11230485
doi: 10.1200/JCO.2001.19.5.1405
Ribeil JA (2022) Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms? 97:4–6
Forni GL, Gianesin B, Musallam KM et al (2023) Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years. Am J Hematol 98:381–387
pubmed: 36588408
doi: 10.1002/ajh.26798
Tomasik J, Basak GW (2022) Inflammasomes – New contributors to blood diseases. Int J Mol Sci 23:8129
pubmed: 35897704
pmcid: 9331764
doi: 10.3390/ijms23158129
Alves PM, Martins PRJ, Dias FDL et al (2008) Sensitivity to cisplatin-induced mutations and elevated chromosomal aberrations in lymphocytes from sickle cell disease patients. Clin Exp Med 8:31–35
pubmed: 18385938
doi: 10.1007/s10238-008-0153-3
Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12:584–596
pubmed: 26122183
doi: 10.1038/nrclinonc.2015.105
Nawas MT, Schetelig J, Damm F et al (2021) The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Rev 46:100744
pubmed: 32896435
doi: 10.1016/j.blre.2020.100744
Wong TN, Ramsingh G, Young AL et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552–555
pubmed: 25487151
doi: 10.1038/nature13968
Kim YI, Pogribny IP, Basnakian AG et al (1997) Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 65:46–52
pubmed: 8988912
doi: 10.1093/ajcn/65.1.46
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutations in human cancers. Science 253:49–53
pubmed: 1905840
doi: 10.1126/science.1905840
Gondek LP, Sheedan VA, Fitzhugh CD (2022) Clonal hematopoiesis and the risk of hematologic malignancies after curative therapies for sickle cell disease. J Clin Med 11:3160
pubmed: 35683547
pmcid: 9181510
doi: 10.3390/jcm11113160
Tolu SS, Wang K, Yan Z et al (2020) Characterization of hematopoiesis in sickle cell disease by prospective isolation of stem and progenitor cells. Cells 9:E2159
doi: 10.3390/cells9102159
Platt OS (2000) Sickle cell anemia as an inflammatory disease. J Clin Invest 106:337–338
pubmed: 10930436
pmcid: 314335
doi: 10.1172/JCI10726
Snetsinger B, Ferrone CK, Rauh MJ (2019) Targeted, amplicon-based, next-generation sequencing to detect age-related clonal hematopoiesis. Methods Mol Biol 2045:167–180
pubmed: 30941718
doi: 10.1007/7651_2019_216
Pincez T, Lee SSK, Ilboudo Y et al (2021) Clonal hematopoiesis in sickle cell disease. Blood 138:2148–2152
pubmed: 34521115
pmcid: 8617438
doi: 10.1182/blood.2021011121
Liggett LA, Cato LD, Weinstock JS et al (2022) Clonal hematopoiesis in sickle cell disease. J Clin Invest 132:e156060
pubmed: 34990411
pmcid: 8843701
doi: 10.1172/JCI156060